Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.420
-0.010 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
2.440
+0.020 (0.83%)
After-hours: Dec 5, 2025, 7:34 PM EST
Editas Medicine Employees
Editas Medicine had 246 employees as of December 31, 2024. The number of employees decreased by 19 or -7.17% compared to the previous year.
Employees
246
Change (1Y)
-19
Growth (1Y)
-7.17%
Revenue / Employee
$188,549
Profits / Employee
-$812,337
Market Cap
236.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EDIT News
- 25 days ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 7 weeks ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha
- 2 months ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 2 months ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Editas Medicine, Inc. - Special Call - Seeking Alpha
- 3 months ago - Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewsWire
- 3 months ago - Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate - GlobeNewsWire